1. 1322 Cetuximab monotherapy and cetuximab plus capecitabine as first-line treatment in elderly patients with RAS- and BRAF wild-type metastatic colorectal cancer. Results of the multicenter phase II trial SAKK 41/10. (September 2015) Authors: Kienle, D.; Winterhalder, R.; Koeberle, D.; Horber, D.; Kueng, M.; Saletti, P.; Helbling, D.; Bastian, S.; Dietrich, D.; Baertschi, D.; Pilop, C.; Von Moos, R. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S194 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Treatment-associated Fatigue in Cancer Patients Treated with Immune Checkpoint Inhibitors; a Systematic Review and Meta-analysis. Issue 10 (October 2016) Authors: Abdel-Rahman, O.; Helbling, D.; Schmidt, J.; Petrausch, U.; Giryes, A.; Mehrabi, A.; Schöb, O.; Mannhart, M.; Zidan, A.; Oweira, H. Journal: Clinical oncology Issue: Volume 28:Issue 10(2016) Page Start: e127 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Treatment-related Death in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. Issue 4 (April 2017) Authors: Abdel-Rahman, O.; Helbling, D.; Schmidt, J.; Petrausch, U.; Giryes, A.; Mehrabi, A.; Schöb, O.; Mannhart, M.; Oweira, H. Journal: Clinical oncology Issue: Volume 29:Issue 4(2017) Page Start: 218 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗